AU2013336410B2 - Drug-protein conjugates - Google Patents

Drug-protein conjugates Download PDF

Info

Publication number
AU2013336410B2
AU2013336410B2 AU2013336410A AU2013336410A AU2013336410B2 AU 2013336410 B2 AU2013336410 B2 AU 2013336410B2 AU 2013336410 A AU2013336410 A AU 2013336410A AU 2013336410 A AU2013336410 A AU 2013336410A AU 2013336410 B2 AU2013336410 B2 AU 2013336410B2
Authority
AU
Australia
Prior art keywords
group
conjugate
maytansine
integer
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013336410A
Other languages
English (en)
Other versions
AU2013336410A1 (en
Inventor
George Badescu
John Burt
Mark Frigerio
Antony Godwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abzena UK Ltd
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Publication of AU2013336410A1 publication Critical patent/AU2013336410A1/en
Application granted granted Critical
Publication of AU2013336410B2 publication Critical patent/AU2013336410B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013336410A 2012-10-24 2013-10-11 Drug-protein conjugates Active AU2013336410B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261717743P 2012-10-24 2012-10-24
US61/717,743 2012-10-24
PCT/GB2013/052662 WO2014064424A1 (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Publications (2)

Publication Number Publication Date
AU2013336410A1 AU2013336410A1 (en) 2015-04-09
AU2013336410B2 true AU2013336410B2 (en) 2017-08-03

Family

ID=49488609

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013336410A Active AU2013336410B2 (en) 2012-10-24 2013-10-11 Drug-protein conjugates

Country Status (19)

Country Link
US (1) US20150283259A1 (cg-RX-API-DMAC7.html)
EP (1) EP2911696B1 (cg-RX-API-DMAC7.html)
JP (1) JP6328649B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150085808A (cg-RX-API-DMAC7.html)
CN (1) CN104755106B (cg-RX-API-DMAC7.html)
AU (1) AU2013336410B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015008311A2 (cg-RX-API-DMAC7.html)
CA (1) CA2884359A1 (cg-RX-API-DMAC7.html)
DK (1) DK2911696T3 (cg-RX-API-DMAC7.html)
ES (1) ES2652513T3 (cg-RX-API-DMAC7.html)
HU (1) HUE037604T2 (cg-RX-API-DMAC7.html)
IL (1) IL237673A0 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN02577A (cg-RX-API-DMAC7.html)
MX (1) MX2015005124A (cg-RX-API-DMAC7.html)
NO (1) NO2789793T3 (cg-RX-API-DMAC7.html)
RU (1) RU2015119557A (cg-RX-API-DMAC7.html)
SG (1) SG11201501955VA (cg-RX-API-DMAC7.html)
WO (1) WO2014064424A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201501996B (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102306490B1 (ko) 2013-03-15 2021-09-28 리제너론 파아마슈티컬스, 인크. 생물학적 활성 분자, 그의 접합체 및 치료 용도
WO2014194030A2 (en) * 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP3038624B1 (en) 2013-08-26 2024-09-25 Regeneron Pharmaceuticals, Inc. Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
US10406198B2 (en) * 2014-05-23 2019-09-10 Novartis Ag Methods for making conjugates from disulfide-containing proteins
EP3148592A2 (en) 2014-06-02 2017-04-05 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
ES2885854T3 (es) 2014-10-14 2021-12-15 Polytherics Ltd Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG
GB2531715A (en) * 2014-10-24 2016-05-04 Polytherics Ltd Novel drug conjugates
US20170290925A1 (en) * 2014-10-24 2017-10-12 Polytherics Limited Conjugates And Conjugating Reagents
SG11201707148PA (en) 2015-03-27 2017-10-30 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
US10509035B2 (en) * 2015-08-07 2019-12-17 Gamamabs Pharma Sa Antibodies, antibody drug conjugates and methods of use
PH12018501589B1 (en) 2016-01-25 2022-08-10 Regeneron Pharma Maytansinoid derivatives, conjugates thereof, and methods of use
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
EP3442595A1 (en) 2016-04-14 2019-02-20 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
EP4282434A3 (en) 2016-06-06 2024-03-06 Abzena (UK) Limited Antibodies, uses thereof and conjugates thereof
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
GB201615725D0 (en) * 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
WO2018086139A1 (en) 2016-11-14 2018-05-17 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
KR20220029725A (ko) 2019-06-29 2022-03-08 항저우 디에이씨 바이오테크 씨오, 엘티디 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법
US11918649B2 (en) 2019-09-18 2024-03-05 Molecular Templates, Inc. PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
AU2021337687A1 (en) 2020-09-04 2023-03-23 CSPC Megalith Biopharmaceutical Co., Ltd., Nectin-4 antibodies and uses thereof
WO2022197945A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
JP2024541058A (ja) 2021-11-03 2024-11-06 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 抗体の特異的共役
CN117147824A (zh) * 2022-05-29 2023-12-01 菲鹏生物股份有限公司 一种抗体缀合物及其应用
CN119161461A (zh) * 2023-06-19 2024-12-20 广东菲鹏生物有限公司 标记Fab抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134976A1 (en) * 2008-04-30 2009-11-05 Immunogen, Inc Potent conjugates and hydrophilic linkers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
NZ566982A (en) * 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
DK2211904T3 (en) * 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
US9005598B2 (en) 2009-03-04 2015-04-14 Polytherics Limited Conjugated proteins and peptides
TW201117814A (en) * 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
IN2014DN10428A (cg-RX-API-DMAC7.html) * 2012-06-19 2015-08-21 Polytherics Ltd

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009134976A1 (en) * 2008-04-30 2009-11-05 Immunogen, Inc Potent conjugates and hydrophilic linkers

Also Published As

Publication number Publication date
CN104755106B (zh) 2018-03-13
CN104755106A (zh) 2015-07-01
EP2911696A1 (en) 2015-09-02
ZA201501996B (en) 2016-01-27
HK1208186A1 (en) 2016-02-26
AU2013336410A1 (en) 2015-04-09
RU2015119557A (ru) 2016-12-20
BR112015008311A2 (pt) 2017-07-04
JP6328649B2 (ja) 2018-05-23
CA2884359A1 (en) 2014-05-01
KR20150085808A (ko) 2015-07-24
ES2652513T3 (es) 2018-02-02
HUE037604T2 (hu) 2018-09-28
IN2015DN02577A (cg-RX-API-DMAC7.html) 2015-09-11
WO2014064424A1 (en) 2014-05-01
SG11201501955VA (en) 2015-04-29
IL237673A0 (en) 2015-04-30
MX2015005124A (es) 2015-10-29
NO2789793T3 (cg-RX-API-DMAC7.html) 2018-01-27
JP2015536329A (ja) 2015-12-21
EP2911696B1 (en) 2017-09-20
DK2911696T3 (en) 2018-01-08
US20150283259A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
AU2013336410B2 (en) Drug-protein conjugates
US20220062436A1 (en) Drug-protein conjugates
US20240293549A1 (en) Conjugates And Conjugating Reagents
KR101972303B1 (ko) 단백질-중합체-약물 접합체
US11865183B2 (en) Conjugates and conjugating reagents comprising a linker that includes at least two (−CH2—CH2—O—) units in a ring
Liu et al. Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates
HK1208186B (en) Drug-protein conjugates
HK1232455A1 (en) Drug-protein conjugates
HK1232455A (en) Drug-protein conjugates
WO2024008102A1 (en) Linker for conjugation
HK1208187B (en) Drug-protein conjugates
WO2025064424A1 (en) Tandem-cleavage linkers for antibody-drug conjugates and uses thereof
Seifalian et al. Sb431542 Inhibitor
NZ728857B2 (en) Materials and methods relating to linkers for use in protein drug conjugates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)